〔Abstract〕Objective To observe the clinical effects of somatostatin combined with propranolol on hepatic cirrhosis with esophageal and gastric varicosis bleeding (EGVB). Methods A total of 96 patients with hepatic cirrhosis and EGVB admitted to Luohe Hospital of Traditional Chinese Medicine from January 2017 to January 2019 were selected and divided into a control group and an observation group according to random number table method, with 48 cases in each group. The control group was given somatostatin treatment, the observation group was given propranolol on the basis of treatment in the control group, and the clinical efficacy of the two groups was compared. Results The total effective rate of the observation group was 89.58%, which was higher than 72.92% of the control group, and the difference was statistically significant (P < 0.05). The hemostatic time and blood transfusion volume in the observation group were less than those in the control group, the differences were statistically significant (P < 0.05). There was no significant difference in rebleeding rate between the two groups (P > 0.05). The portal vein pressure (PVP) level in the observation group was lower than those in the control group at 24 h and 48 h after treatment, the differences were statistically significant (P < 0.05). The levels of fibrinogen (FIB) and D-dimer (D-D) in the observation group were higher than those in the control group after 5 days of treatment, and the differences were statistically significant (P < 0.05). There were no significant differences in the incidence of nausea and vomiting, diarrhea, bradycardia and hyponatremia between the observation group and the control group (P > 0.05). Conclusion Somatostatin combined with propranolol can effectively reduce PVP，improve bleeding and enhance the treatment effects of hepatic cirrhosis with EGVB.